CAMBRIAN BIOPHARMA
Cambrian Biopharma is building the medicines that will modernize healthcare in the 21st century – therapeutics to lengthen healthspan, the period of life spent in good health. As a Distributed Development Company (or DisCo), Cambrian is advancing multiple scientific breakthroughs, each targeting a biological driver of aging. Our approach is to develop interventions that treat specific diseases first, then deploy them as preventative medicines to improve quality of life/overall quality of life as we age.
CAMBRIAN BIOPHARMA
Industry:
Biopharma Biotechnology Life Science
Founded:
2019-01-01
Status:
Active
Email Addresses:
[email protected]
Total Funding:
160 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager Global Site Tag Euro
Similar Organizations
Arbor Biotechnologies
Arbor Biotechnologies is an operator of a bio-discovery company intended to provide human diagnostic development services.
Arcellx
Arcellx is a clinical-stage biotechnology company that provides patients with immune cell therapies.
Axcella
Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.
Bicara Therapeutics
Bicara Therapeutics develops dual-action cancer therapies, combining targeted treatments with tumor modulators for enhanced impact.
Cerevance
Cerevance is a developer of novel therapeutics intended to advance new medicines for serious neurological diseases.
Demetrix
Demetrix is a biotechnology company dedicated to researching and producing bioactive ingredients.
Enliven Therapeutics
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
NGM Biopharmaceuticals
NGM Biopharmaceuticals is a drug discovery company developing biotherapeutics for the gastrointestinal endocrine system.
Omniome
Omniome engages in developing a proprietary DNA sequencing platform capable of delivering unsurpassed sequencing accuracy.
Current Advisors List
Current Employees Featured
Founder
Investors List
Future Ventures
Future Ventures investment in Series C - Cambrian Biopharma
SALT Fund
SALT Fund investment in Series C - Cambrian Biopharma
Alumni Ventures
Alumni Ventures investment in Series C - Cambrian Biopharma
Anthos Capital
Anthos Capital investment in Series C - Cambrian Biopharma
Apeiron Investment Group
Apeiron Investment Group investment in Series C - Cambrian Biopharma
infinitas capital group
infinitas capital group investment in Series C - Cambrian Biopharma
Kliwla Family Office AG
Kliwla Family Office AG investment in Series C - Cambrian Biopharma
Moore Capital
Moore Capital investment in Series C - Cambrian Biopharma
infinitas capital group
infinitas capital group investment in Series B - Cambrian Biopharma
Mike Novogratz
Mike Novogratz investment in Series B - Cambrian Biopharma
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-05-19 | Oviva Therapeutics | Cambrian Biopharma investment in Seed Round - Oviva Therapeutics | 11.5 M USD |
| 2021-06-23 | Vita Therapeutics | Cambrian Biopharma investment in Series A - Vita Therapeutics | 32 M USD |
| 2021-04-13 | Arcellx | Cambrian Biopharma investment in Series C - Arcellx | N/A |
| 2021-01-11 | Sensei Biotherapeutics | Cambrian Biopharma investment in Series B - Sensei Biotherapeutics | 30 M USD |
| 2020-10-07 | Sensei Biotherapeutics | Cambrian Biopharma investment in Series A - Sensei Biotherapeutics | 28.5 M USD |
Newest Events participated
More informations about "Cambrian Biopharma"
About - Cambrian Bio
Cambrian’s sourcing and development engine allows us to identify promising science, deploy capital and teams of drug development experts, and provide stewardship to advance new medicines that will lengthen healthspan. By …See details»
Cambrian Biopharma - Crunchbase Investor Profile & Investments
Cambrian Biopharma is building the medicines that will modernize healthcare in the 21st century – therapeutics to lengthen healthspan, the period of life spent in good health. As a Distributed …See details»
Team - Cambrian Bio
White has spent the past 13 years in various IT roles. For the past eight years, he has worked at two biopharma companies. Prior to joining Cambrian, White led the IT Service Management …See details»
Cambrian Bio - LinkedIn
Cambrian Bio is a clinical-stage drug development company building the medicines that will modernize healthcare in the 21st century. Our focus lies in creating innovative therapeutics designed to ...See details»
Cambrian Bio Company Profile 2024: Valuation, …
Cambrian Bio General Information Description. Developer of a portfolio of medicines designed to target the causes of age-related diseases. The company develops therapies and medicines to create interventions that treat specific …See details»
Cambrian Biopharma - Funding, Financials, Valuation & Investors
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors ... Venture Round - Cambrian …See details»
Hear how Cambrian BioPharma is reinventing drug …
May 3, 2023 Cambrian BioPharma bills itself as a new pharmaceutical company with a revolutionary approach to developing and managing drug development. James Peyer, PhD, co-founded the company in 2019, and it ...See details»
Cambrian Biopharma CAM-1108 - lifespan.io
Cambrian Biopharma is a biotechnology company focused on developing treatments that target the underlying biology of aging to extend human healthspan. They aim to create a pipeline of …See details»
Cambrian Bio launches Amplifier Therapeutics to develop clinical …
Mar 14, 2023 The organization will develop ATX-304, a pan-AMPK (AMP-activated protein kinase) activator. ... Cambrian BioPharma [email protected] SOURCE Cambrian Biopharma. …See details»
Cambrian BioPharma Announces its Scientific Advisory Board led …
NEW YORK, Sept. 14, 2022 /PRNewswire/ -- Cambrian BioPharma, a multi-asset longevity biotech, today announces its Scientific Advisory Board (SAB) and appointment of C. David …See details»
Cambrian Bio
NEW YORK , Nov. 4, 2022 /PRNewswire/ -- Cambrian BioPharma, a multi-asset longevity biotech, today announced that its CEO, James Peyer, has been selected as "BioTech …See details»
Cambrian Biopharma - Contacts, Employees, Board Members
Cambrian Biopharma has 4 current employee profiles, including EVP, Clinical Development Ruth Thieroff-Ekerdt. Cambrian Biopharma has 5 board members and advisors, including Martin …See details»
Cambrian Biopharma Closes $100 Million Series C to Advance …
NEW YORK, Oct. 26, 2021 /PRNewswire/ -- Cambrian Biopharma, a multi-asset longevity biotech, today announced the close of an oversubscribed Series C financing, which raised …See details»
Mission, Vision & Core Values of Cambrian Biopharma
Oct 12, 2024 The Cambrian Biopharma Mission, Vision & Core Values. Cambrian Biopharma is a cutting-edge biotechnology company dedicated to revolutionizing the pharmaceutical …See details»
Cambrian Biopharma CAM-6019 - lifespan
Cambrian Biopharma is a biotechnology company focused on developing treatments that target the underlying biology of aging to extend human healthspan. They aim to create a pipeline of …See details»
Cambrian Bio
Sep 14, 2022 NewYork, New York, September 14, 2022 - Cambrian BioPharma, a multi-asset longevity biotech, today announces its Scientific Advisory Board (SAB) and appointment of C. …See details»
Cambrian secures $100M series C for Roivant-like approach to …
Oct 26, 2021 Cambrian Biopharma is on a mission to slow down the aging process and treat humans before they even develop cancer or Alzheimer's disease. Before the biotech can test …See details»
Vita Therapeutics Closes $31 Million Series B Financing to Develop …
Baltimore, MD, October 12, 2022 – Vita Therapeutics, a cell engineering company harnessing the power of genetics to develop novel cellular therapies to treat muscular dystrophies and …See details»
Science - Cambrian Bio
Cambrian is advancing multiple scientific breakthroughs, each targeting a biological driver of aging. Our approach is to develop interventions that treat specific diseases first, then deploy …See details»